SKYE BIOSCIENCE INC. - COMMON STOCK

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model

15 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience to Conduct Meetings at Piper Sandler Conference

14 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

20 Mar 2025 16:01:00 By Nasdaq GlobeNewswire

Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025

14 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

27 Feb 2025 18:00:58 By Nasdaq GlobeNewswire

Skye Bioscience to Participate in SXSW Session on Obesity

24 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience to Present at TD Cowen Health Care Conference

20 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience Announces Participation in February Conferences

04 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience Provides 2025 Look Ahead and Year in Review

13 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience to Present at J.P. Morgan Healthcare Conference

19 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences

18 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

14 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

07 Nov 2024 16:01:00 By Nasdaq GlobeNewswire

Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model

04 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience to Announce Third Quarter 2024 Results

01 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board

29 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences

21 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan

23 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer

03 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences

26 Aug 2024 07:00:00 By Nasdaq GlobeNewswire